New Insulin Injection and Infusion Recommendations

Mayo Clinic Proceedings Publishes New Insulin Injection and Infusion Recommendations1
New recommendations based on findings from the largest Injection Technique survey performed: more than 13,000 insulin-injecting patients from 42 countries, including Australia 2,3

BD (Becton, Dickinson and Company), a leading global medical technology company, and the ADEA (Australian Diabetes Educators Association), welcome the Mayo Clinic Proceedings’ publication of new insulin delivery recommendations for health care professionals caring for patients who inject their diabetes medication, as well as two articles describing the results from a global Injection Technique Questionnaire survey of people with insulin-requiring diabetes.

The three articles, appearing in the September issue of the esteemed U.S. medical journal Mayo Clinic Proceedings, are the result of the largest injection technique survey ever performed for people with diabetes. The survey was conducted in 423 centers across 42 countries and gained responses from more than 13,000 people.
Two of the Mayo Clinic Proceedings articles examine the key findings from the injection technique survey; the third article presents new insulin delivery recommendations which are intended to help shape local and regional injection guidelines around the world.

Hilary Crilly, Managing Director at BD Australia and New Zealand, believes the implementation of these new FITTER Recommendations locally will bring about significant improvements for all health care professionals involved in supporting the management of diabetes, as well as for their patients who inject their diabetes medication.

“At BD, we strive to deliver on our company’s purpose of advancing the world of health across everything we do and addressing challenging global health issues.

This is evident through the innovative medical products and devices we make and the partnerships we have with leading local and international health care professionals to publish evidence-based diabetes education in peer-reviewed publications,” said Ms Crilly.

“Over 180 diabetes experts from 54 countries analysed the results of this unprecedented global injection technique survey, sponsored by BD. This is a clear indication of the level of interest that exists across the world on the critical role that injection technique plays in diabetes care. The experts’ individual and collective professional input played a significant role in bringing the FITTER Insulin Injection & Infusion Recommendations to fruition.”

“BD looks forward to working with Australia’s peak diabetes bodies, including the ADEA, to review current local guidelines to include these new evidence-based and comprehensive recommendations.”

Giuliana Murfet, ADEA President said the ADEA Clinical Practice Review Committee will review the new FITTER Insulin Injection & Infusion Recommendations with the view to updating the current ADEA Clinical Recommendations titled ‘Clinical Guiding Principles for Subcutaneous Injection Technique’ published in October 2015.

“The ADEA strongly supports evidenced-based, best practice diabetes education and care. Clinical practice informed by sound and contemporary evidence is critical for ensuring optimal insulin delivery and safety for both patients and clinicians. We look forward to reviewing the FITTER Insulin Injection & Infusion Recommendations in more detail over the coming months,” Ms Murfet said.

To access the Mayo Clinic Proceedings articles, visit the below links:
• New Insulin Delivery Recommendations: New Insulin Delivery Recommendations: http://www.sciencedirect.com/science/article/pii/S0025619616303214
• Worldwide Injection Technique Questionnaire Study: Population Parameters and Injection Practices – http://www.sciencedirect.com/science/article/pii/S0025619616303226
• Worldwide Injection Technique Questionnaire Study: Injecting Complications and the Role of the Professional – http://www.sciencedirect.com/science/article/pii/S0025619616303263

* FITTER stands for the Forum for Injection Technique & Therapy Expert Recommendations and is an international program sponsored by BD. The FITTER Workshop was held in Rome, Italy in October 2015.

About BD
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance cellular studies and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit
www.bd.com.

About FITTER
FITTER is the latest in a series of scientific seminars sponsored by BD to improve the management of Diabetes for health care professionals and patients around the world. FITTER seeks to promote evidence based clinical best practice, safety and self-care of diabetes injectable and infused therapies which will lead to improved health outcomes, well-being, lower health care costs and reduced burden on care providers and wider society. The congress marked a major milestone in the history of diabetes care, bringing about a paradigm shift where Injection and Infusion Technique is regarded as important as insulin, diet and activity.
FITTER provides all clinicians who care for people with diabetes using injectable therapies with the most up-to-date clinical evidence, analysis of the results of the largest injection technique study in the world and the ‘new’ international injection technique recommendations, delivered to the highest academic and scientific standards.

Full implementation of the ‘new’ International Injection Technique Recommendations could help patients to:
• Achieve their HbA1c targets
• Reduce the incidence of lipohypertrophy
• Reduce their excess insulin use
• Avoid complications
• Improve their health outcomes

New recommendations are based on the results of the largest injection technique study in the world, organized by BD from February 2014 to June 2015, with 13,289 respondents from 42 countries. By learning from best practice globally, health care professionals may be better placed to help their patients.

References:
1. Frid AH, Hirsch LJ, Menchior AR et al. Mayo Clin Proc. September 2016:91(9):1212-1223.
2. Frid AH, Hirsch LJ, Menchior AR et al. Mayo Clin Proc. September 2016:91(9):1224-1230.
3. Frid AH, Kreugel G, Grassi G et al. Mayo Clin Proc. September 2016:91(9):1231-1255